Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study

Background Standard oncology tools are inadequate to distinguish which older patients are at higher risk of developing chemotherapy‐related complications. Materials and Methods Patients over 70 years of age starting new chemotherapy regimens were prospectively included in a multicenter study. A prec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The oncologist (Dayton, Ohio) Ohio), 2020-10, Vol.25 (10), p.e1516-e1524
Hauptverfasser: Feliu, Jaime, Jiménez‐Munárriz, Beatriz, Basterretxea, Laura, Paredero, Irene, Llabrés, Elisenda, Antonio‐Rebollo, Maite, Losada, Beatriz, Espinosa, Enrique, Gironés, Regina, Custodio, Ana Belén, del Mar Muñoz, María, Díaz‐Almirón, Mariana, Gómez‐Mediavilla, Jeniffer, Pinto, Alvaro, Torregrosa, María‐Dolores, Soler, Gema, Cruz, Patricia, Higuera, Oliver, Molina‐Garrido, María José
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Standard oncology tools are inadequate to distinguish which older patients are at higher risk of developing chemotherapy‐related complications. Materials and Methods Patients over 70 years of age starting new chemotherapy regimens were prospectively included in a multicenter study. A prechemotherapy assessment that included sociodemographics, tumor/treatment variables, and geriatric assessment variables was performed. Association between these factors and the development of grade 3–5 toxicity was examined by using logistic regression. Results A total of 551 patients were accrued. Chemotherapy doses (odds ratio [OR] 1.834; 95% confidence interval [CI] 1.237–2.719) and creatinine clearance (OR 0.989; 95% CI 0.981–0.997) were the only factors independently associated with toxicity. Only 19% of patients who received reduced doses of chemotherapy and had a creatinine clearance ≥40 mL/minute had grade 3–4 toxicity, compared with 38% of those who received standard doses or had a creatinine clearance
ISSN:1083-7159
1549-490X
1549-490X
DOI:10.1634/theoncologist.2019-0701